0001683168-19-001392.txt : 20190507
0001683168-19-001392.hdr.sgml : 20190507
20190507172542
ACCESSION NUMBER: 0001683168-19-001392
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20190507
DATE AS OF CHANGE: 20190507
EFFECTIVENESS DATE: 20190507
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0000908259
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133679168
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-339030
FILM NUMBER: 19804274
BUSINESS ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-635-7000
MAIL ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: OXIGENE INC
DATE OF NAME CHANGE: 19930628
D
1
primary_doc.xml
X0708
D
LIVE
0000908259
MATEON THERAPEUTICS INC
701 GATEWAY BLVD.
SUITE 210
SOUTH SAN FRANCISCO
CA
CALIFORNIA
94080
650-635-7000
DELAWARE
OXiGENE, Inc.
OXIGENE INC
Corporation
true
Vuong
Trieu
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Director
William
Schwieterman
701 Gateway Blvd., Suite 210
South San Francisco
CA
CALIFORNIA
94080
Director
Matthew
Loar
701 Gateway Blvd., Suite 210
South San Francisco
CA
CALIFORNIA
94080
Executive Officer
Fatih
Uckun
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Chulho
Park
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2019-04-22
false
true
true
false
38000
1200000
600000
600000
Offering of convertible debentures convertible into shares of the Issuer's common stock in the event of default. In addition, 700,000 shares of the Issuer's common stock were issued as commitment fee to two of the investors.
false
4
0
0
0
false
MATEON THERAPEUTICS INC
/s/ Vuong Trieu
Vuong Trieu
CEO
2019-05-07